Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Gene Expression Signatures to Guide Treatment of Ovarian Cancer

By LabMedica International staff writers
Posted on 23 Sep 2008
A molecular diagnostic test will be developed to guide clinicians in their choice of currently available treatments for ovarian cancer.

Transgenomic (Omaha, NE, USA) has partnered with Key Genomics (Charlottesville VA, USA) to improve ovarian cancer patient outcomes through personalized medicine. More...
Transgenomic's highly sensitive technologies for DNA mutation detection and analysis will complement and enhance Key Genomics predictive algorithm, CO-eXpression ExtrapolatioN (COXEN), which combines genomic and pharmacologic response data on a set of widely used cancer cell lines to generate molecular signatures of patient response to specific anticancer agents. This innovative test is intended to provide the optimal therapy recommendation according to the molecular characteristics of each patient's tumor.

Ovarian cancers are often diagnosed at the advanced stage of disease, after the tumor has spread beyond the ovary. Initial investigation of COXEN-derived genomic signatures in clinical trials has demonstrated that the test can distinguish responders from patients who do not benefit from a therapy.

Tim Gallagher CEO of Key Genomics CEO, said, "An algorithm that could quickly sort molecular information about a patient's particular tumor, and then match this information with the right drug treatment would be a valuable medical breakthrough. COXEN has the potential to bring significant healthcare and economic value by personalizing cancer therapy by using such a method-- an algorithm based on in vitro response to anticancer drugs.”

Related Links:
Transgenomic
Key Genomics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.